SUTRO BIOPHARMA, INC. Earnings Per Share (Diluted)
SUTRO BIOPHARMA, INC. (STRO) reported Earnings Per Share (Diluted) of -$2.33 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$2.33.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$2.94.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2025-12-31 was $0.21, a 42.49% decline year-over-year.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.67.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for fiscal 2025 was -$22.49.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for fiscal 2024 was -$29.40.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for fiscal 2023 was -$1.78.
- SUTRO BIOPHARMA, INC. earnings per share, diluted for fiscal 2022 was -$2.35.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.33 10-Q · filed 2026-08-12 | -$5.19 10-Q · filed 2026-08-12 | $1.96 derived: net income ÷ weighted average shares · filed 2026-08-12 | $6.94 derived: net income ÷ weighted average shares · filed 2026-08-12 | |||
| 2026-03-31 | -$2.94 10-Q · filed 2026-05-14 | $0.83 derived: net income ÷ weighted average shares · filed 2026-08-12 | $3.53 derived: net income ÷ weighted average shares · filed 2026-08-12 | $5.48 derived: net income ÷ weighted average shares · filed 2026-08-12 | |||
| 2025-12-31 | $0.21 derived: net income ÷ weighted average shares · filed 2026-04-22 | $1.55 derived: net income ÷ weighted average shares · filed 2026-04-22 | $2.76 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$22.49 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$0.67 10-Q · filed 2025-11-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.71 10-Q · filed 2025-11-06 | $9.39 derived: net income ÷ weighted average shares · filed 2026-08-12 | |||
| 2025-06-30 | -$1.35 10-Q · filed 2026-08-12 | -$0.14 10-Q · filed 2025-08-07 | -$10.31 10-Q · filed 2026-08-12 | -$1.04 10-Q · filed 2025-08-07 | $2.70 derived: net income ÷ weighted average shares · filed 2026-08-12 | $8.77 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2025-03-31 | -$9.08 10-Q · filed 2026-05-14 | -$0.91 10-Q · filed 2025-05-08 | $1.60 derived: net income ÷ weighted average shares · filed 2026-08-12 | $5.71 derived: net income ÷ weighted average shares · filed 2026-08-12 | $44.05 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||
| 2024-12-31 | $0.37 derived: net income ÷ weighted average shares · filed 2026-04-22 | $2.16 derived: net income ÷ weighted average shares · filed 2026-04-22 | $16.55 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$29.40 10-K · filed 2026-03-23 | -$2.96 10-K · filed 2025-03-13 | ||
| 2024-09-30 | -$0.59 10-Q · filed 2025-11-06 | -$1.19 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$2.07 10-Q · filed 2025-11-06 | -$1.74 derived: net income ÷ weighted average shares · filed 2026-04-22 | |||
| 2024-06-30 | -$0.59 10-Q · filed 2025-08-07 | -$1.49 10-Q · filed 2025-08-07 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-04-22 | |||
| 2024-03-31 | -$0.59 10-Q · filed 2025-08-07 | -$0.95 10-Q · filed 2024-05-13 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-04-22 | ||
| 2023-12-31 | $0.51 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-22 | -$1.78 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$0.81 10-Q · filed 2024-11-13 | -$1.45 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$2.30 10-Q · filed 2024-11-13 | -$2.91 derived: net income ÷ weighted average shares · filed 2025-03-13 | |||
| 2023-06-30 | -$0.64 10-Q · filed 2024-08-13 | -$1.49 10-Q · filed 2024-08-13 | -$2.10 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$2.50 derived: net income ÷ weighted average shares · filed 2025-03-13 | |||
| 2023-03-31 | -$0.85 10-Q · filed 2024-05-13 | -$1.46 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.86 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$2.42 derived: net income ÷ weighted average shares · filed 2025-03-13 | |||
| 2022-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$0.99 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$1.54 derived: net income ÷ weighted average shares · filed 2025-03-13 | -$2.35 10-K · filed 2025-03-13 | |||
| 2022-09-30 | -$0.37 10-Q · filed 2023-11-13 | -$0.92 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.74 10-Q · filed 2023-11-13 | -$2.56 derived: net income ÷ weighted average shares · filed 2024-03-25 | |||
| 2022-06-30 | -$0.55 10-Q · filed 2023-08-10 | -$1.39 10-Q · filed 2023-08-10 | -$2.22 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$2.89 derived: net income ÷ weighted average shares · filed 2024-03-25 | |||
| 2022-03-31 | -$0.84 10-Q · filed 2023-05-15 | -$1.66 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$2.33 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$2.47 derived: net income ÷ weighted average shares · filed 2024-03-25 | |||
| 2021-12-31 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$1.49 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$1.63 derived: net income ÷ weighted average shares · filed 2024-03-25 | -$2.29 10-K · filed 2024-03-25 | |||
| 2021-09-30 | -$0.67 10-Q · filed 2022-11-08 | -$0.80 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.46 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | -$0.13 10-Q · filed 2022-08-08 | -$0.79 10-Q · filed 2022-08-08 | |||||
| 2020-12-31 | -$1.48 10-K · filed 2021-03-18 | -$1.10 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.35 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$0.99 10-K · filed 2023-03-30 | |||
| 2020-09-30 | $0.45 10-Q · filed 2021-11-10 | $1.35 derived: net income ÷ weighted average shares · filed 2021-11-10 | $0.90 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $0.94 10-Q · filed 2021-08-09 | $0.36 10-Q · filed 2021-08-09 | |||||
| 2020-03-31 | -$0.84 10-K · filed 2021-03-18 | ||||||
| 2019-09-30 | -$0.56 10-Q · filed 2020-11-05 | -$1.16 derived: net income ÷ weighted average shares · filed 2021-03-18 | -$1.79 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | -$0.60 10-Q · filed 2020-08-06 | -$1.22 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |